Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 1/20 | 0.53 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.52 |
| ▸ | P2RX2 | Q9UBL9 | 2/20 | 0.52 |
| ▸ | GPR17 | Q13304 | 2/20 | 0.51 |
| ▸ | P2RY6 | Q15077 | 8/20 | 0.50 |
| ▸ | P2RY2 | P41231 | 7/20 | 0.50 |
| ▸ | P2RY4 | P51582 | 4/20 | 0.50 |
| ▸ | P2RY12 | Q9H244 | 3/20 | 0.50 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.50 |
| ▸ | RNASEL | Q05823 | 3/20 | 0.49 |
| ▸ | P2RY1 | P47900 | 2/20 | 0.48 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL625829 | 0.83 | P2RY1 (0.57) | P2RX3P2RX2P2RY6P2RY2P2RY12 | |
| SCHEMBL8028076 | 0.78 | P2RX3 (0.48) | P2RX3P2RX2GPR17P2RY6P2RY2 | |
| SCHEMBL6704190 | 0.78 | ATIC (0.57) | P2RX3P2RX2P2RY2P2RX4RNASEL | |
| SCHEMBL4377679 | 0.78 | RNASEL (0.51) | P2RX3P2RX2GPR17P2RY6P2RY2 | |
| SCHEMBL2449672 | 0.77 | ATIC (0.56) | P2RX3P2RY2RNASELP2RY1 | |
| SCHEMBL3444128 | 0.75 | PDE2A (0.45) | NT5E | |
| SCHEMBL13269025 | 0.75 | ADORA2A (0.41) | NT5E | |
| SCHEMBL10768528 | 0.75 | SLC29A1 (0.38) | NT5EP2RX3GPR17ENPP1 | |
| SCHEMBL5721746 | 0.74 | P2RX3 (0.52) | P2RX3P2RX2GPR17P2RY6P2RY2 | |
| SCHEMBL6883604 | 0.74 | GPR17 (0.64) | NT5EP2RX3P2RX2GPR17P2RY6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120135092-A1 | INHIBITORS OF RecA ACTIVITIES FOR CONTROL OF ANTIBIOTIC-RESISTANT BACTERIAL PATHOGENS | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL, THE | 2012-05-31 | — | — | US | claimed |
| US-20060199768-A1 | Inhibitors of RecA activities for control of antibiotic-resistant bacterial pathogens | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2006-09-07 | — | — | US | claimed |
| US-20120135092-A1 | INHIBITORS OF RecA ACTIVITIES FOR CONTROL OF ANTIBIOTIC-RESISTANT BACTERIAL PATHOGENS | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL, THE | 2012-05-31 | — | — | US | disclosed |
| US-20100292135-A1 | INHIBITORS OF RecA ACTIVITIES FOR CONTROL OF ANTIBIOTIC-RESISTANT BACTERIAL PATHOGENS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-11-18 | — | — | US | disclosed |
| US-20060199768-A1 | Inhibitors of RecA activities for control of antibiotic-resistant bacterial pathogens | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2006-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060199768-A1 | Inhibitors of RecA activities for control of antibiotic-resistant bacterial pathogens | RECQL, DNA2, WRN | NT5E 601/4885P2RX3 1480/4885P2RX2 1581/4885 |
| US-20100292135-A1 | INHIBITORS OF RecA ACTIVITIES FOR CONTROL OF ANTIBIOTIC-RESISTANT BACTERIAL PATHOGENS | RECQL, DNA2, WRN | NT5E 601/4885P2RX3 1480/4885P2RX2 1581/4885 |
| US-20120135092-A1 | INHIBITORS OF RecA ACTIVITIES FOR CONTROL OF ANTIBIOTIC-RESISTANT BACTERIAL PATHOGENS | RECQL, WRN, ADAR | NT5E 296/4885P2RX3 757/4885P2RX2 763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.